by Dr. Ed Weber | Dec 28, 2022 | PCa Commentary
Metastases Directed Therapy refers to targeted radiation, i.e., such as CyberKnife, directed at a few metastatic lesions, (osseous or nodal), usually 3 – 5, for the purpose of controlling all imageable disease, delaying cancer progression and, if not accompanied...
by Dr. Ed Weber | Nov 8, 2022 | PCa Commentary
Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a transient, heterogeneous state that progresses to metastatic disease. nmCRPC is defined as a rising PSA after primary therapy in association with a castrate level of testosterone (<50 ng/mL) while...
by Dr. Ed Weber | Oct 25, 2022 | PCa Commentary
The key to optimal outcomes in active surveillance is careful patient selection and monitoring of participants during AS. MRI guided biopsy at initial diagnosis: Lee et al., Korean J Radiol. 2021 Jul, argue that in men in whom there is a clinical suspicion of prostate...
by Dr. Ed Weber | Sep 21, 2022 | PCa Commentary
Any man diagnosed with prostate cancer is likely aware that lowering testosterone (T) levels achieves control of the cancer at various stages of the disease. Question: What is the underlying biology and function of that therapeutic maneuver (androgen deprivation...
by Dr. Ed Weber | Aug 24, 2022 | PCa Commentary
The incidence of metastatic prostate cancer at diagnosis, i.e., metastatic hormone-sensitive prostate cancer has increased, partly due to the fallout from the 2012 Task Force recommendation against screening, particularly increasing in men older than 75 years. This...
by Dr. Ed Weber | Jul 20, 2022 | PCa Commentary
Provenge (Dendreon, Inc, ‘Sipuleucel-T’) is an autologous (i.e., based on a patient’s own cells) vaccine targeted to the highly expressed prostatic acid phosphatase (PAP) antigen on malignant prostate cells. It was FDA approved based on the IMPACT trial reporting a...